Markets:

Overview

News

Currencies

International

Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

75.54 -0.21 (-0.28%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast ↗

September 30, 2024

Truist Securities raises the price target for Corcept Therapeutics to $76, driven by robust Korlym sales and promising relacorilant trials. The analyst highlights significant growth potential in the...

Via Benzinga

Forecasting The Future: 6 Analyst Projections For Corcept Therapeutics ↗

September 18, 2024

Via Benzinga

NASDAQ:CORT is not too expensive for the growth it is showing. ↗

September 17, 2024

Investors should take note ofCORCEPT THERAPEUTICS INC (NASDAQ:CORT), a growth stock that remains attractively priced.

Via Chartmill

NASDAQ:CORT: a strong growth stock preparing for the next leg up?. ↗

September 09, 2024

Exploring the Growth Potential of CORCEPT THERAPEUTICS INC (NASDAQ:CORT) as It Nears a Breakout.

Via Chartmill

For those who appreciate growth without the sticker shock, NASDAQ:CORT is worth considering. ↗

August 27, 2024

Don't overlook CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

NASDAQ:CORT: a strong growth stock preparing for the next leg up?. ↗

August 16, 2024

CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—Positioned as a High-Growth Stock, Ready for a Potential Breakout.

Via Chartmill

NASDAQ:CORT is not too expensive for the growth it is showing. ↗

August 05, 2024

Don't overlook NASDAQ:CORT—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

Unveiling 8 Analyst Insights On Corcept Therapeutics ↗

July 30, 2024

Via Benzinga

6 Analysts Have This To Say About Corcept Therapeutics ↗

June 17, 2024

Via Benzinga

CORT Stock Earnings: Corcept Therapeutics Beats EPS, Beats Revenue for Q2 2024 ↗

July 29, 2024

CORT stock results show that Corcept Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

July 29, 2024

From Corcept Therapeutics Incorporated

Via GlobeNewswire

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

July 22, 2024

From Corcept Therapeutics Incorporated

Via GlobeNewswire

Why NASDAQ:CORT Is a Promising High-Growth Stock in the Midst of Consolidation. ↗

July 15, 2024

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) qualifies as a high growth stock and is consolidating.

Via Chartmill

NASDAQ:CORT is not too expensive for the growth it is showing. ↗

May 31, 2024

NASDAQ:CORT is showing good growth, while it is not too expensive.

Via Chartmill

Corcept Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) ↗

May 29, 2024

Via Benzinga

Investors seeking growth at a reasonable cost should explore NASDAQ:CORT. ↗

July 15, 2024

For those who appreciate growth without the sticker shock, CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is worth considering.

Via Chartmill

7 Biotech Stocks to Boost Your Portfolio to Peak Health ↗

June 26, 2024

With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas.

Via InvestorPlace

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for June 2024 ↗

June 26, 2024

Selecting strong buy biotech stocks isn’t easy when most of them don’t make money. Here are three possibilities to meet this challenge.

Via InvestorPlace

Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association’s Scientific Sessions

June 24, 2024

From Corcept Therapeutics Incorporated

Via GlobeNewswire

While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. ↗

June 24, 2024

CORCEPT THERAPEUTICS INC (NASDAQ:CORT) is showing good growth, while it is not too expensive.

Via Chartmill

Concerpt Therapeutics Shares Are Trading Lower: What You Need To Know ↗

June 14, 2024

Corcept Therapeutics Inc. (NASDAQ: CORT) shares are trading lower Friday afternoon following a report suggesting Teva Pharmaceuticals Inc. (NYSE: TEVA) has sued the company, accusing it of a monopoly...

Via Benzinga

Topics Lawsuit

Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

June 14, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 03, 2024

Via Benzinga

Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing’s Syndrome)

June 03, 2024

From Corcept Therapeutics Incorporated

Via GlobeNewswire

Nvidia, Insmed, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday ↗

May 28, 2024

Via Benzinga

Why Applied DNA Sciences Shares Are Trading Lower By Around 68%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

May 28, 2024

Via Benzinga

Why Mid-Cap Corcept Therapeutics Stock Trading Higher On Tuesday? ↗

May 28, 2024

Corcept Therapeutics announced the GRACE Phase 3 trial results for relacorilant in Cushing's syndrome, showing significant improvements in hypertension and hyperglycemia.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 28, 2024

Via Benzinga

Corcept Announces Primary Endpoint Met in Pivotal Phase 3 GRACE Trial of Relacorilant in Patients With Hypercortisolism (Cushing’s Syndrome)

May 28, 2024

From Corcept Therapeutics Incorporated

Via GlobeNewswire

While growth is established for NASDAQ:CORT, the stock's valuation remains reasonable. ↗

May 10, 2024

Don't overlook CORCEPT THERAPEUTICS INC (NASDAQ:CORT)—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

All News about Corcept Therapeutics Incorporated - Common Stock

Starting at $3.75/week.

Subscribe Today